Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · IEX Real-Time Price · USD
2.430
-0.110 (-4.33%)
May 2, 2024, 2:47 PM EDT - Market closed
Innate Pharma Revenue
In the year 2023, Innate Pharma had annual revenue of $68.49M with 11.63% growth.
Revenue (ttm)
$68.49M
Revenue Growth
+11.63%
P/S Ratio
2.82
Revenue / Employee
$382,626
Employees
179
Market Cap
196.45M USD
Revenue Chart
* The company reports in EUR currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 68.49M | 7.13M | 11.63% |
Dec 31, 2022 | 61.36M | 33.28M | 118.57% |
Dec 31, 2021 | 28.07M | -57.02M | -67.01% |
Dec 31, 2020 | 85.09M | -10.92M | -11.37% |
Dec 31, 2019 | 96.01M | -11.98M | -11.09% |
Dec 31, 2018 | 107.99M | 55.15M | 104.37% |
Dec 31, 2017 | 52.84M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Auna S.A. | 1.04B |
Lifecore Biomedical | 103.27M |
Zevra Therapeutics | 27.46M |
uniQure | 15.84M |
Lineage Cell Therapeutics | 8.95M |
Century Therapeutics | 2.24M |
Cardiff Oncology | 488.00K |
IPHA News
- 17 days ago - Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024 - Business Wire
- 17 days ago - Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients - Business Wire
- 22 days ago - Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate - Business Wire
- 23 days ago - Innate Pharma Announces Its Participation in Upcoming Investor Conference - Business Wire
- 27 days ago - Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F - Business Wire
- 6 weeks ago - Innate Pharma Reports Full Year 2023 Financial Results and Business Update - Business Wire
- 6 weeks ago - Innate Pharma Announces Its Participation to Upcoming Investor Conference - Business Wire
- 7 weeks ago - Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results - Business Wire